Page last updated: 2024-11-06

2-phenyl-4,5-dichloro-3-pyridazinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID72813
CHEMBL ID610198
SCHEMBL ID1461789
MeSH IDM0074200

Synonyms (73)

Synonym
HMS2612K09
1-fenyl-4,5-dichlor-6-pyridazinon
wln: t6nnvj br& dg eg
nsc-224369
NCI60_014437
NCI60_001850
nsc-642642
3(2h)-pyridazinone,5-dichloro-2-phenyl-
4,5-dichloro-2-phenyl-2h-pyridazin-3-one
MLS000332063
smr000221555
4,5-dichloro-2,3-dihydro-2-phenylpyridazin-3-one
einecs 216-917-6
nsc 642642
3(2h)-pyridazinone, 4,5-dichloro-2-phenyl-
nsc 224369
4,5-dichloro-2-phenyl-3(2h)-pyridazinone
ai3-18651
brn 0175852
2-phenyl-4,5-dichloro-3-pyridazinone
1-fenyl-4,5-dichlor-6-pyridazinon [czech]
nsc224369
1698-53-9
nsc642642
4,5-dichloro-2-phenyl-pyridazin-3-one
4,5-dichloro-2-phenylpyridazin-3-one
2(2h)-pyridazinone, 4,5-dichloro-2-phenyl-
CHEMDIV2_002909 ,
STK350677
4,5-dichloro-2-phenylpyridazin-3(2h)-one ,
1-phenyl-4,5-dichloro-6-pyridazone, >=99%
pyridazinone, 2-42
bdbm33355
cid_72813
AKOS000313144
HMS1377E05
CHEMBL610198
AC-907/34127045
4,5-dichloro-2-cyclohexa-1,3-dien-1-yl-pyridazin-3-one;4,5-dichloro-2-phenylpyridazin-3(2h)-one
A811147
4,5-dichloro-2-phenyl-2,3-dihydropyridazin-3-one
NCGC00246299-01
1-phenyl-4,5-dichloro-6-pyridazone
SCHEMBL1461789
CCG-129262
5-24-02-00024 (beilstein handbook reference)
unii-n78ah78wrv
n78ah78wrv ,
3(2h)-pyridazinone,4,5-dichloro-2-phenyl-
FT-0617168
5M-603S
4,5-dichlor-2-phenyl-3(2h)-pyridazinon
4,5-dichloro-1-phenylpyridaz-6-one
2-phenyl-4,5-dichloro-3(2h)-pyridazinone
1-phenyl-4,5-dichloropyridazin-6-one
4,5-dichloro-2-phenyl-pyridazinone
4,5-dichloro-2-phenyl-3(2h)-pyridazinone #
J-640178
1-phenyl-4,5-dichloro-5-pyridazone
W-109120
AC-27715
HMS3438D08
DTXSID60168751
J-800179
SR-01000403864-1
sr-01000403864
mfcd00006470
CS-0128769
D71015
SY101526
EN300-02004
D5325
Z56851285
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00320.003245.467312,589.2998AID2517
Nrf2Homo sapiens (human)Potency3.16230.09208.222223.1093AID624171
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency14.12540.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency18.35640.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency3.08680.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency31.62280.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
P53Homo sapiens (human)Potency3.16230.07319.685831.6228AID504706
IDH1Homo sapiens (human)Potency4.10950.005210.865235.4813AID686970
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.16230.01262.451825.0177AID485313
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency5.62340.010039.53711,122.0200AID1479
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency70.79463.548119.542744.6684AID743266
huntingtin isoform 2Homo sapiens (human)Potency8.91250.000618.41981,122.0200AID1688
ras-related protein Rab-9AHomo sapiens (human)Potency0.70790.00022.621531.4954AID485297
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency3.54810.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency3.54810.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency3.54810.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.61010.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency3.88600.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.62280.00419.962528.1838AID2675
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency25.11890.058010.694926.6086AID602310
Glycoprotein hormones alpha chainHomo sapiens (human)Potency2.51194.46688.344810.0000AID624291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine-1-phosphate receptor 4Homo sapiens (human)IC50 (µMol)1.86000.08900.70152.0290AID1692
XBP1Homo sapiens (human)IC50 (µMol)5.23000.16005.404910.0000AID504313
caspase recruitment domain family, member 15Homo sapiens (human)IC50 (µMol)49.74700.62154.05046.6330AID651553
sphingosine 1-phosphate receptor 1Homo sapiens (human)IC50 (µMol)8.70601.41804.64948.7060AID1821
receptor-interacting serine/threonine-protein kinase 2 isoform 1Homo sapiens (human)IC50 (µMol)49.74700.62154.05046.6330AID651553
DNA damage-inducible transcript 3 proteinMus musculus (house mouse)IC50 (µMol)9.45000.16003.995910.0000AID504322
Beta lactamase (plasmid)Pseudomonas aeruginosaIC50 (µMol)49.74700.70915.05497.7510AID651552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)5.44800.160024.4900236.5000AID2382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PAX8Homo sapiens (human)AC506.10000.04885.435469.1700AID687027
MSHDrosophila melanogaster (fruit fly)AC5016.31000.20909.578848.6900AID743444
Microphthalmia-associated transcription factorHomo sapiens (human)AC5011.65560.015010.904946.0480AID493073; AID493102; AID493177; AID493191; AID540346
Hsf1 proteinMus musculus (house mouse)AC5014.40300.171030.8718167.9780AID493085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID453287Inhibition of Staphylococcus aureus sortase A deltaN59 mutant assessed as Dap(Dnp) hydrolysis by FRET assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors.
AID1799237Fluorescence Resonance Energy Transfer (FRET) Assay from Article 10.1016/j.bmc.2009.08.067: \\Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors.\\2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's1 (10.00)18.2507
2000's2 (20.00)29.6817
2010's5 (50.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]